- In early July 2026, Revolution Medicines reported Phase 1/2 data showing that its oral RAS(ON) G12D inhibitor zoldonrasib, in combinations with standard chemotherapy or daraxonrasib, produced high response and disease control rates with manageable safety in metastatic pancreatic ductal adenocarcinoma, supporting ongoing and planned global Phase 3 RASolute trials.
- The findings highlight how a targeted RAS G12D approach could reshape treatment options in a mutation affecting tens of thousands of new US cancer patients each year, where no approved targeted therapies currently exist.
- Next, we’ll examine how these early zoldonrasib pancreatic results might influence Revolution Medicines’ RAS-focused investment narrative and risk-reward profile.
We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Revolution Medicines Investment Narrative Recap
To own Revolution Medicines today, you have to believe its RAS(ON) platform can turn early pancreatic cancer success into multiple approved drugs before the cash burn becomes problematic. The new zoldonrasib data strengthens the near term catalyst around the RASolute 305 and 309 Phase 3 programs, but it also raises the stakes on a single target class that remains the company’s biggest concentration risk.
One closely linked development is the June start of patient treatment in RASolute 305, the global Phase 3 trial of zoldonrasib plus standard chemotherapy in first line RAS G12D metastatic pancreatic cancer. Together with the fresh Phase 1/2 results, this anchors zoldonrasib as a central piece of the near term investment story, with trial execution and readouts joining cash use as key watchpoints for upcoming catalysts.
Yet behind the strong data, investors should be aware of how quickly heavy R&D spending can become a problem if...
Read the full narrative on Revolution Medicines (it's free!)
Revolution Medicines’ narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies an earnings increase of about $1.3 billion from -$1.1 billion today.
Uncover how Revolution Medicines' forecasts yield a $133.70 fair value, a 29% downside to its current price.
Exploring Other Perspectives
Before this news, the most optimistic analysts were modeling about US$2.1 billion of revenue and US$424.4 million of earnings by 2029, a view that assumes fast approvals and smooth multi trial execution, while others worry that any operational hiccups in these large Phase 3 programs could push that timeline out significantly.
Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 3x more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.
No Opportunity In Revolution Medicines?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- Find 44 companies with promising cash flow potential yet trading below their fair value.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com